Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE

MLA

Roy Fleischmann, et al. “Long-Term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE.” Rheumatology and Therapy, vol. 11, no. 3, Mar. 2024, pp. 599–615. EBSCOhost, https://doi.org/10.1007/s40744-024-00658-1.

APA

Roy Fleischmann, Ricardo Blanco, Filip Van den Bosch, Louis Bessette, Yanna Song, Sara K. Penn, Erin McDearmon-Blondell, Nasser Khan, Kelly Chan, & Eduardo Mysler. (2024). Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE. Rheumatology and Therapy, 11(3), 599–615. https://doi.org/10.1007/s40744-024-00658-1

Chicago

Roy Fleischmann, Ricardo Blanco, Filip Van den Bosch, Louis Bessette, Yanna Song, Sara K. Penn, Erin McDearmon-Blondell, Nasser Khan, Kelly Chan, and Eduardo Mysler. 2024. “Long-Term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE.” Rheumatology and Therapy 11 (3): 599–615. doi:10.1007/s40744-024-00658-1.